Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.

Antibodies, Neutralizing / immunology Antibodies, Viral / immunology BNT162 Vaccine COVID-19 / blood COVID-19 Vaccines / immunology HEK293 Cells Humans Immunity, Humoral Mutation / genetics ROC Curve SARS-CoV-2 / genetics
COVID-19 RBD SARS-CoV-2 escape mRNA vaccines neutralizing antibodies spike variants

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
29 04 2021
Historique:
received: 12 02 2021
revised: 26 02 2021
accepted: 08 03 2021
pubmed: 21 3 2021
medline: 14 5 2021
entrez: 20 3 2021
Statut: ppublish

Résumé

Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2. Five of the 10 pseudoviruses, harboring receptor-binding domain mutations, including K417N/T, E484K, and N501Y, were highly resistant to neutralization. Cross-neutralization of B.1.351 variants was comparable to SARS-CoV and bat-derived WIV1-CoV, suggesting that a relatively small number of mutations can mediate potent escape from vaccine responses. While the clinical impact of neutralization resistance remains uncertain, these results highlight the potential for variants to escape from neutralizing humoral immunity and emphasize the need to develop broadly protective interventions against the evolving pandemic.

Identifiants

DOI: 10.1016/j.cell.2021.03.013 PMID: 33743213 PMC: PMC7953441
pubmed: 33743213
pii: S0092-8674(21)00298-1
doi: 10.1016/j.cell.2021.03.013
pmc: PMC7953441
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
COVID-19 Vaccines 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2372-2383.e9

Subventions

Organisme : NIDA NIH HHS
ID : DP2 DA040254
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI146779
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007245
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007753
Pays : United States

Commentaires et corrections

Type : UpdateOf
Type : ErratumIn
Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Cell Res. 2021 Jun;31(6):720-722
pubmed: 33893398
Cell Rep. 2021 Mar 23;34(12):108890
pubmed: 33713594
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Science. 2021 Feb 5;371(6529):
pubmed: 33303686
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Virol. 2004 Oct;78(19):10628-35
pubmed: 15367630
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
Science. 2020 Nov 13;370(6518):856-860
pubmed: 33082293
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Viruses. 2020 Dec 09;12(12):
pubmed: 33316947
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Cell Mol Immunol. 2021 Apr;18(4):1061-1063
pubmed: 33633321
Vaccines (Basel). 2020 Dec 28;9(1):
pubmed: 33379160
Nat Med. 2021 Mar;27(3):440-446
pubmed: 33531709
J Biomol Screen. 2013 Apr;18(4):453-61
pubmed: 23112084
Viruses. 2020 May 06;12(5):
pubmed: 32384820
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Biosaf Health. 2020 Dec;2(4):226-231
pubmed: 32864605
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99
pubmed: 33476315

Auteurs

Wilfredo F Garcia-Beltran (WF)

Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.

Evan C Lam (EC)

Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.

Kerri St Denis (K)

Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.

Adam D Nitido (AD)

Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.

Zeidy H Garcia (ZH)

Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.

Blake M Hauser (BM)

Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.

Jared Feldman (J)

Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.

Maia N Pavlovic (MN)

Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA.

David J Gregory (DJ)

Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA; Pedriatric Infectious Disease, Massachusetts General Hospital for Children, Boston, MA 02114, USA.

Mark C Poznansky (MC)

Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA 02129, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

Alex Sigal (A)

Africa Health Research Institute, Durban 4001, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4041, South Africa; Max Planck Institute for Infection Biology, Berlin 10117, Germany.

Aaron G Schmidt (AG)

Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.

A John Iafrate (AJ)

Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.

Vivek Naranbhai (V)

Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa.

Alejandro B Balazs (AB)

Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA. Electronic address: abalazs@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Multiple SARS-CoV-2 variants escape...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Multiple SARS-CoV-2 variants escape...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Vaccin BNT162 › Multiple SARS-CoV-2 variants escape...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Multiple SARS-CoV-2 variants escape...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Multiple SARS-CoV-2 variants escape...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HEK293 › Multiple SARS-CoV-2 variants escape...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Multiple SARS-CoV-2 variants escape...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité humorale › Multiple SARS-CoV-2 variants escape...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Multiple SARS-CoV-2 variants escape...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Courbe ROC › Multiple SARS-CoV-2 variants escape...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Multiple SARS-CoV-2 variants escape...